Author:
Akbari Abolfazl,Amanpour Saeid,Muhammadnejad Samad,Ghahremani Mohammad Hossein,Ghaffari Seyed Hamidollah,Dehpour Ahmad Reza,Mobini Gholam Reza,Shidfar Fatemeh,Abastabar Mahdi,Khoshzaban Ahad,Faghihloo Ebrahim,Karimi Abbas,Heidari Mansour
Abstract
Abstract
Background
Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment.
Methods
To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively.
Results
Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls.
Conclusion
Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
Publisher
Springer Science and Business Media LLC
Subject
Applied Mathematics,General Mathematics
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献